2026-10-27 11:30:27 UTC#520803duplicateconfirmednews
Jiangsu Hengrui Pharmaceuticals stock news
Jiangsu Hengrui Pharmaceuticals stock news. Deduplicated factual headlines, scored for importance, with entity sentiment and the sectors, countries, and asset classes affected. Updates open into the storyline.
See the full wire20 wire items
2026-10-27 10:18:24 UTC#520169duplicateconfirmednews
JPMorgan Chase reduces stake in Jiangsu Hengrui Pharmaceuticals to 9.74% from 10.26% per HKEX filing
reutersimportance 0.30trust 0.90JPMorgan Chase & Co. -0.20Jiangsu Hengrui Pharmaceuticals Co., Ltd. +0.20Hong Kong Exchanges and Clearing Limited 0
2026-10-27 10:00:13 UTC#519913newconfirmednews
JPMorgan Chase & Co. reduces stake in Jiangsu Hengrui Pharmaceuticals to 9.74% from 10.26% per HKEX filing
first_squawkimportance 0.40trust 0.90JPMorgan Chase & Co. -0.20Jiangsu Hengrui Pharmaceuticals Co., Ltd. 0Hong Kong Exchanges and Clearing Limited 0
2026-10-27 09:59:44 UTC#519947duplicateconfirmednews
Jiangsu Hengrui Pharmaceuticals Q3 profit rose 88.9% on licensing deals
2026-10-27 09:53:14 UTC#519890duplicateconfirmednews
Jiangsu Hengrui Pharmaceuticals reports Q3 net profit of 2.5 billion yuan, up 88.9% on licensing deals
2026-10-27 09:06:00 UTC#519701duplicateconfirmeddata release
Jiangsu Hengrui Pharmaceuticals reports 9-month net profit of CNY6.92 billion, up 21% year-over-year
2026-10-21 02:29:00 UTC#490251duplicateconfirmedpress release
Hengrui Pharma to present 64 oncology research findings at ESMO 2026 Congress
pr newswireimportance 0.30trust 0.90Jiangsu Hengrui Pharmaceuticals Co., Ltd. +0.30European Society for Medical Oncology 0
2026-10-21 02:29:00 UTC#490250duplicateconfirmedpress release
Hengrui Pharma to showcase 64 oncology research findings at ESMO 2026 Congress
pr newswireimportance 0.30trust 0.90Jiangsu Hengrui Pharmaceuticals Co., Ltd. +0.30European Society for Medical Oncology +0.10
2026-10-16 11:56:35 UTC#471697newconfirmednews
BlackRock reduces stake in Jiangsu Hengrui Pharmaceuticals H-shares to 5.72% from 6.33% per HKEX filing
reutersimportance 0.30trust 0.90BlackRock, Inc. -0.20Jiangsu Hengrui Pharmaceuticals Co., Ltd. +0.20Hong Kong Exchanges and Clearing Limited 0
2026-10-09 10:25:36 UTC#437556newconfirmednews
BlackRock reduces stake in Jiangsu Hengrui Pharmaceuticals H-shares to 5.76% from 6.34% per HKEX filing
reutersimportance 0.30trust 0.90BlackRock, Inc. -0.20Jiangsu Hengrui Pharmaceuticals Co., Ltd. +0.20Hong Kong Exchanges and Clearing Limited 0
2026-10-02 17:26:47 UTC#406603newconfirmednews
UBS Group AG reduces long position in Jiangsu Hengrui Pharmaceuticals H-shares to 4.59% from 5.17%
reutersimportance 0.30trust 0.90UBS Group AG -0.20Jiangsu Hengrui Pharmaceuticals Co., Ltd. +0.20Hong Kong Exchanges and Clearing Limited 0
2026-09-30 14:11:29 UTC#392332duplicateconfirmedanalysis
FT Analysis: Novo Nordisk's Hengrui licensing deal reflects strategic weaknesses
2026-09-30 12:17:51 UTC#391265duplicateconfirmednews
Major drugmakers continue trend of licensing Chinese biotech assets, Reuters reports
reutersimportance 0.30trust 0.90Novo Nordisk A/S +0.30Jiangsu Hengrui Pharmaceuticals Co., Ltd. +0.40Merck & Co., Inc. +0.20+2 entities
2026-09-30 07:33:12 UTC#389590updatereportednews
Novo Nordisk to begin Phase 1 trials for obesity pill licensed from Hengrui, First Squawk reports
first_squawkimportance 0.40trust 0.60Novo Nordisk A/S +0.40Jiangsu Hengrui Pharmaceuticals Co., Ltd. +0.40
2026-09-30 07:33:09 UTC#389591updatereportednews
Novo Nordisk executive says Hengrui-licensed weight loss pill could be available by 2030
first_squawkimportance 0.40trust 0.60Novo Nordisk A/S +0.30Jiangsu Hengrui Pharmaceuticals Co., Ltd. +0.30
2026-09-29 05:15:00 UTC#381785duplicateconfirmednews
Novo Nordisk Licenses Obesity Drug HRS-1596 From Hengrui Pharma in Deal Worth Up to $2.6 Billion
dow_jonesimportance 0.40trust 0.90Novo Nordisk A/S +0.40Jiangsu Hengrui Pharmaceuticals Co., Ltd. +0.40HRS-1596 +0.40+2 entities
2026-09-29 04:47:54 UTC#381665duplicateconfirmednews
Novo Nordisk to pay $300M upfront for global rights to Hengrui's HRS-1596 in $2.6B deal
first_squawkimportance 0.30trust 0.70Novo Nordisk A/S +0.30Jiangsu Hengrui Pharmaceuticals Co., Ltd. +0.40HRS-1596 +0.30
2026-09-29 04:44:41 UTC#381667duplicateconfirmednews
Novo Nordisk licenses weight-management drug HRS-1596 from Jiangsu Hengrui in $2.6B deal
reutersimportance 0.50trust 0.90Jiangsu Hengrui Pharmaceuticals Co., Ltd. +0.60Novo Nordisk A/S +0.30HRS-1596 +0.40
2026-09-29 04:43:36 UTC#381647newconfirmednews
Novo Nordisk licenses oral GLP-1/GIP agonist HRS-1596 from Hengrui Pharma in deal worth up to $2.6 billion
reutersimportance 0.70trust 0.90Novo Nordisk A/S +0.50Jiangsu Hengrui Pharmaceuticals Co., Ltd. +0.50HRS-1596 +0.50
2026-09-25 10:30:53 UTC#367967newconfirmednews
UBS Group AG increases long position in Jiangsu Hengrui Pharmaceuticals H-shares to 5.23% from 4.43%, HKEX filing shows
reutersimportance 0.40trust 0.90UBS Group AG +0.30Jiangsu Hengrui Pharmaceuticals Co., Ltd. +0.30Hong Kong Exchanges and Clearing Limited 0